Novartis tests pill to quiet chaotic heart rhythms

NCT ID NCT07217067

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new oral medication called PKN605 can safely reduce the amount of time people spend in atrial fibrillation (AF), a common irregular heartbeat. About 165 adults with a history of AF will take either PKN605 or a placebo pill daily for 24 weeks while their heart rhythm is closely monitored. The main goal is to see if the drug lowers AF burden—the percentage of time the heart is in this irregular rhythm.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Cardiology Associates of North MS
RECRUITING

Tupelo, Mississippi, 38801, United States

Contact Email: •••••@•••••

Contact
Intermountain Medical Center
RECRUITING

Murray, Utah, 84107, United States

Contact

Contact Email: •••••@•••••
Novartis Investigative Site
RECRUITING

London, Ontario, N6A 5W9, Canada
Novartis Investigative Site
RECRUITING

Newmarket, Ontario, L3Y 2P6, Canada
Novartis Investigative Site
RECRUITING

Toronto, Ontario, M5B 1W8, Canada
Novartis Investigative Site
RECRUITING

Montreal, Quebec, H1T 1C8, Canada
Novartis Investigative Site
RECRUITING

Montreal, Quebec, H2X 1R9, Canada
Novartis Investigative Site
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
Novartis Investigative Site
RECRUITING

Québec, Quebec, G1V 4G5, Canada
Novartis Investigative Site
RECRUITING

Sherbrooke, Quebec, J1H 5N4, Canada
Novartis Investigative Site
RECRUITING

Beijing, Beijing Municipality, 100013, China
Novartis Investigative Site
RECRUITING

Xi'an, 223001, China
Novartis Investigative Site
RECRUITING

Bad Homburg, 61348, Germany
Novartis Investigative Site
RECRUITING

Berlin, 10787, Germany
Novartis Investigative Site
RECRUITING

Berlin, 13353, Germany
Novartis Investigative Site
RECRUITING

Hamburg, 20099, Germany
Novartis Investigative Site
RECRUITING

Hamburg, 20246, Germany
Novartis Investigative Site
RECRUITING

Delft, South Holland, 2625 AD, Netherlands
Novartis Investigative Site
RECRUITING

Goes, Zeeland, 4462 RA, Netherlands
Novartis Investigative Site
RECRUITING

Groningen, 9713 GZ, Netherlands
Novartis Investigative Site
RECRUITING

Veldhoven, 5504 DB, Netherlands
Novartis Investigative Site
RECRUITING

Singapore, Singapore, S308433, Singapore
Novartis Investigative Site
RECRUITING

Singapore, 119074, Singapore
Novartis Investigative Site
RECRUITING

Singapore, 169609, Singapore
Novartis Investigative Site
RECRUITING

Brighton, East Sussex, BN2 5BE, United Kingdom
Novartis Investigative Site
RECRUITING

Newcastle upon Tyne, Tyne and Wear, NE7 7DN, United Kingdom
Novartis Investigative Site
RECRUITING

Liverpool, L14 3PE, United Kingdom
Novartis Investigative Site
RECRUITING

London, W12 0HS, United Kingdom
Swedish Heart and Vascular Clinic
RECRUITING

Seattle, Washington, 98122, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Weill Cornell Medical Center
RECRUITING

New York, New York, 10021, United States

Contact

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ATRIAL FIBRILLATION